Insulet Statistics
Total Valuation
Insulet has a market cap or net worth of $9.92 billion. The enterprise value is $10.33 billion.
| Market Cap | 9.92B |
| Enterprise Value | 10.33B |
Important Dates
The last earnings date was Wednesday, August 5, 2026, before market open.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Insulet has 69.35 million shares outstanding. The number of shares has decreased by -1.19% in one year.
| Current Share Class | 69.35M |
| Shares Outstanding | 69.35M |
| Shares Change (YoY) | -1.19% |
| Shares Change (QoQ) | -1.14% |
| Owned by Insiders (%) | 0.32% |
| Owned by Institutions (%) | 105.25% |
| Float | 69.06M |
Valuation Ratios
The trailing PE ratio is 27.01 and the forward PE ratio is 20.81. Insulet's PEG ratio is 1.05.
| PE Ratio | 27.01 |
| Forward PE | 20.81 |
| PS Ratio | 3.25 |
| Forward PS | 2.84 |
| PB Ratio | 6.98 |
| P/TBV Ratio | 7.90 |
| P/FCF Ratio | 33.78 |
| P/OCF Ratio | 19.41 |
| PEG Ratio | 1.05 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.81, with an EV/FCF ratio of 35.19.
| EV / Earnings | 27.54 |
| EV / Sales | 3.38 |
| EV / EBITDA | 16.81 |
| EV / EBIT | 20.04 |
| EV / FCF | 35.19 |
Financial Position
The company has a current ratio of 2.48, with a Debt / Equity ratio of 0.67.
| Current Ratio | 2.48 |
| Quick Ratio | 1.51 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 1.54 |
| Debt / FCF | 3.23 |
| Interest Coverage | 8.77 |
Financial Efficiency
Return on equity (ROE) is 26.02% and return on invested capital (ROIC) is 21.31%.
| Return on Equity (ROE) | 26.02% |
| Return on Assets (ROA) | 9.71% |
| Return on Invested Capital (ROIC) | 21.31% |
| Return on Capital Employed (ROCE) | 21.30% |
| Weighted Average Cost of Capital (WACC) | 9.78% |
| Revenue Per Employee | $565,444 |
| Profits Per Employee | $69,500 |
| Employee Count | 5,400 |
| Asset Turnover | 0.92 |
| Inventory Turnover | 1.90 |
Taxes
In the past 12 months, Insulet has paid $119.40 million in taxes.
| Income Tax | 119.40M |
| Effective Tax Rate | 24.14% |
Stock Price Statistics
The stock price has decreased by -56.75% in the last 52 weeks. The beta is 1.09, so Insulet's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | -56.75% |
| 50-Day Moving Average | 154.23 |
| 200-Day Moving Average | 217.43 |
| Relative Strength Index (RSI) | 42.58 |
| Average Volume (20 Days) | 1,786,725 |
Short Selling Information
The latest short interest is 3.84 million, so 5.53% of the outstanding shares have been sold short.
| Short Interest | 3.84M |
| Short Previous Month | 4.65M |
| Short % of Shares Out | 5.53% |
| Short % of Float | 5.55% |
| Short Ratio (days to cover) | 2.99 |
Income Statement
In the last 12 months, Insulet had revenue of $3.05 billion and earned $375.30 million in profits. Earnings per share was $5.30.
| Revenue | 3.05B |
| Gross Profit | 2.17B |
| Operating Income | 515.60M |
| Pretax Income | 494.70M |
| Net Income | 375.30M |
| EBITDA | 614.90M |
| EBIT | 515.60M |
| Earnings Per Share (EPS) | $5.30 |
Balance Sheet
The company has $534.90 million in cash and $948.40 million in debt, with a net cash position of -$413.50 million or -$5.96 per share.
| Cash & Cash Equivalents | 534.90M |
| Total Debt | 948.40M |
| Net Cash | -413.50M |
| Net Cash Per Share | -$5.96 |
| Equity (Book Value) | 1.42B |
| Book Value Per Share | 20.51 |
| Working Capital | 1.10B |
Cash Flow
In the last 12 months, operating cash flow was $511.20 million and capital expenditures -$217.50 million, giving a free cash flow of $293.70 million.
| Operating Cash Flow | 511.20M |
| Capital Expenditures | -217.50M |
| Depreciation & Amortization | 99.30M |
| Net Borrowing | -609.00M |
| Free Cash Flow | 293.70M |
| FCF Per Share | $4.23 |
Margins
Gross margin is 71.07%, with operating and profit margins of 16.89% and 12.29%.
| Gross Margin | 71.07% |
| Operating Margin | 16.89% |
| Pretax Margin | 16.20% |
| Profit Margin | 12.29% |
| EBITDA Margin | 20.14% |
| EBIT Margin | 16.89% |
| FCF Margin | 9.62% |
Dividends & Yields
Insulet does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.19% |
| Shareholder Yield | 1.19% |
| Earnings Yield | 3.78% |
| FCF Yield | 2.96% |
Analyst Forecast
The average price target for Insulet is $171.91, which is 20.18% higher than the current price. The consensus rating is "Buy".
| Price Target | $171.91 |
| Price Target Difference | 20.18% |
| Analyst Consensus | Buy |
| Analyst Count | 25 |
| Revenue Growth Forecast (3Y) | 16.33% |
| EPS Growth Forecast (3Y) | 23.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Insulet has an Altman Z-Score of 8.46 and a Piotroski F-Score of 8.
| Altman Z-Score | 8.46 |
| Piotroski F-Score | 8 |